News

The Maryland-based Insilico Medicine claimed that GENTRL can fast track the drug discovery process from years to days. The company is said to have validated the AI technology

Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type

Results suggest that Entresto, an essential treatment for HFrEF, not only positively impacts a biomarker shown to be associated with prognosis of clinical outcomes in HFrEF, but also

Topline data from the study were published on 3 July 20191, which showed a significant reduction in hyperglycemia, body weight and waist size compared to placebo. The entire

The phase III trial has demonstrated that Xofluza was a well-tolerated and efficient potential treatment for flu in otherwise healthy children aged one to less than 12 years

The late-stage trials – ASCLEPIOS I and II probed the efficacy and safety of ofatumumab 20mg given as a once-monthly subcutaneous injection, in comparison to daily once oral

Anifrolumab has demonstrated a statistically-significant and clinically-meaningful reduction in disease activity compared to placebo in the trial.  Both arms received standard of care in the study. Anifrolumab is

VNRX-5133 is an injectable beta-lactamase inhibitor (BLI) that features selective and potent in vitro activity against both serine- and metallo-beta-lactamases (MBLs), including ESBL, OXA, KPC, NDM, and VIM

The Breakthrough Therapy Designation was based on Phase 1 and Phase 2 data evaluating nirogacestat as a monotherapy in patients with desmoid tumors. Desmoid tumors are rare and